Chronic Graft-Versus-Host Disease

Researchers found a direct relationship between cutaneous chronic graft-versus-host disease and health-related quality-of-life domains that are not currently included as measurements in clinical trials, according to a study.

The FDA approved axatilimab-csfr for certain patients with chronic graft-versus-host disease.

This year’s ASH Annual Meeting featured several high-impact abstracts.

SAN DIEGO — Axatilimab conferred clinically meaningful and durable responses at three dose levels among individuals with chronic graft-versus-host disease, randomized study results showed.

SALT LAKE CITY — Abatacept demonstrated efficacy among patients with steroid-refractory chronic graft-versus-host-disease, according to phase 2 study results.